Abbott Laboratories (NYSE: ABT) has reported earnings for its fourth fiscal quarter (ending December 31) of $5.27 versus $0.92 for the same period a year ago — an increase of 473%. E.P.S. were $7.64 for the latest four quarters through December 31 versus $3.28 for the same period a year ago — an increase of 133%.
Recent Price Action
Abbott Laboratories (NYSE: ABT) stock closed at $117.78 on 1/22/25 after a modest gain of 0.8%. Moreover, trading volume in this advance was exceptionally high at 257% of normal. The stock has risen 4.1% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Abbott Laboratories has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing contradictory signals. Abbott Laboratories has a poor Appreciation Score of 24 but a slightly positive Power Rating of 61, leading to the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment